Budesonide versus fluticasone for treatment of eosinophilic esophagitis ABSTRACT Eosinophilic esophagitis (EoE) is an emerging immune-mediated disease defined by abnormal infiltration of eosinophils into the esophageal mucosa, leading to dysphagia, progressive esophageal stenosis, and food impaction. Though initially thought to be rare, the incidence and prevalence are rising dramatically, and over the past decade EoE has rapidly become a major cause of upper gastrointestinal morbidity. The treatment of EoE, however, remains rudimentary and data are needed to inform practice. Corticosteroids are currently the mainstay of therapy for EoE, but there are no FDA-approved medications for EoE. Instead, asthma preparations are used, most commonly fluticasone in a multi-dose inhaler (MDI) or aqueous budesonide. These medications are swallowed, rather than inhaled, to coat the esophagus, but it is unknown whether fluticasone or budesonide is the most effective first line agent. It is also unknown how durable the response to these medications are, and whether baseline measurement of tissue biomarkers can predict treatment response. These are crucial and unanswered questions in EoE. We have recently conducted the first and only randomized trial directly comparing two topical formulations for treatment of EoE, and found that swallowing viscous slurry of budesonide was more effective than nebulizing and then swallowing an aqueous budesonide solution. However, viscous budesonide has never been directly compared with fluticasone, and these two medications are most commonly prescribed for EoE. We also have preliminary data showing that levels of major basic protein, eotaxin-3, and mast cell tryptase determined by immunohistochemical staining of esophageal biopsies predict treatment response.
The specific aims of this project are 1) to determine whether viscous budesonide is more effective than fluticasone MDI for improving esophageal eosinophil counts and symptoms of dysphagia in patients with EoE after an initial treatment course; 2) to determine whether treatment with viscous budesonide results in less symptomatic and histologic recurrence than fluticasone MDI one year after the initial treatment course; and 3) to determine whether increased baseline staining of esophageal biopsies for major basic protein, eotaxin-3, and mast cell tryptase is associated with histologic response in EoE patients treated with topical corticosteroids. To achieve these aims, we will conduct a randomized, double-blind, clinical trial comparing viscous budesonide to fluticasone MDI. This innovative and hypothesis-driven study is backed by strong preliminary data generated by the PI while he was supported by an NIH career development award. It will be conducted by an established and unique multidisciplinary team with nationally recognized expertise in EoE, clinical trials, epidemiology, pathology, and translational science. The results will have a major clinical impact on the treatment algorithm for EoE by determining which medications doctors should use first and allowing them to predict treatment response. Data from this study will also readily lead to future trials of individualized treatment protocols for patients with EoE.
Eosinophilic esophagitis (EoE), a newly recognized disease with rapidly increasing incidence, prevalence, and recognition, is characterized by the abnormal presence of eosinophils in the esophageal lining, leading to difficulty swallowing, progressive esophageal stenosis, and food impaction. The goals of this research are to conduct a randomized, double-blind, clinical trial to determine which of two commonly used topical corticosteroid formulations, budesonide or fluticasone, most effectively treats EoE, and to determine whether treatment response can be predicted with pre-treatment testing. The proposed research will impact clinic practice by determining the most effective and long-lasting first line medication for EoE, and allowing doctors to predict which patients will respond to treatment.
| Reed, Craig C; Dellon, Evan S (2018) Patient-Reported Outcomes in Esophageal Diseases. Clin Gastroenterol Hepatol 16:305-310 |
| Jensen, Elizabeth T; Kuhl, Jonathan T; Martin, Lisa J et al. (2018) Early-life environmental exposures interact with genetic susceptibility variants in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 141:632-637.e5 |
| Philpott, Hamish; Dellon, Evan S (2018) The role of maintenance therapy in eosinophilic esophagitis: who, why, and how? J Gastroenterol 53:165-171 |
| Dellon, Evan S; Hirano, Ikuo (2018) Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology 154:319-332.e3 |
| Reed, Craig C; Koutlas, Nathaniel T; Robey, Benjamin S et al. (2018) Prolonged Time to Diagnosis of Eosinophilic Esophagitis Despite Increasing Knowledge of the Disease. Clin Gastroenterol Hepatol 16:1667-1669 |
| Dellon, E S; Lin, L; Beitia, R et al. (2018) Serum autoantibodies against epithelial cell adhesion molecules as disease biomarkers of eosinophilic esophagitis. Clin Exp Allergy 48:343-346 |
| Hines, Brittany T; Rank, Matthew A; Wright, Benjamin L et al. (2018) Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review. Ann Allergy Asthma Immunol 121:218-228 |
| Reed, Craig C; Fan, Claire; Koutlas, Nathaniel et al. (2018) Compounded Oral Viscous Budesonide is Effective and Provides a Durable Response in Eosinophilic Esophagitis. HSOA J Gastroenterol Hepatol Res 7:2509-2515 |
| Kim, Hannah P; Reed, Craig C; Herfarth, Hans H et al. (2018) Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis. Clin Gastroenterol Hepatol 16:1992-1994 |
| Jensen, Elizabeth T; Dellon, Evan S (2018) Environmental factors and eosinophilic esophagitis. J Allergy Clin Immunol 142:32-40 |
Showing the most recent 10 out of 35 publications
